Frost Radar™: Predictive Genetic Testing Technologies, 2023

Frost Radar™: Predictive Genetic Testing Technologies, 2023

A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines

Predictive genetic testing (PGT) comprises analysis of genes, the whole genome, or exomes to predict the risk of a wide range of disorders. It can have long-term implications in preventive healthcare practices, including delayed onset of disease, treatment management, pharmacogenomics, and general wellness. One outcome of the COVID-19 pandemic has been increased focus on preventive healthcare practices from a consumer wellness perspective, and PGT technology complements this desire for preventive and personalized healthcare and wellness monitoring tools. As such, PGT platforms are likely to experience increased global uptake in the next 5 years.

Industry convergence is rising among consumer genetic testing, diagnostic, and pharma companies due to increasing focus on holistic and hyper-personalized healthcare practices. Also, collaboration with pharma and diagnostic companies is on the rise as companies look to deliver targeted therapeutic innovations. This is likely to advance new product development for precision medicine applications in the future. This Frost Radar provides insights across leading clinical and predictive consumer genetics companies that use microarrays, whole genome sequencing (WGS), whole exome sequencing (WES), and targeted sequencing platforms. Key applications areas for such technologies include pharmacogenomic, prenatal, reproductive health, newborn, hereditary cancer risks, rare disease risk, and health and wellness assessment. Emerging application areas for PGT technologies include population-scale genomics for drafting nationwide preventive healthcare guidelines.

Next-generation sequencing (NGS) technologies have high growth potential to fuel new advances in the global PGT landscape. Technology advances in artificial intelligence (AI) and machine learning (ML) platforms will help users derive actionable healthcare insights from a large pool of genomic data. Integration of these advanced technologies is also likely to fuel progress tied to improving insights across population-scale genomics studies. Leading companies in the PGT space are collaborating with pharma companies to develop precision diagnostic and therapeutic innovations. Some companies are also looking to leverage the large-scale genomic data for population genomic analyses.

Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar. The publication presents competitive profiles of each company on the Frost Radar considering their strengths and the opportunities that best fit those strengths.